RE: earlier RNS29 Jan 2021 08:53
DrQu, I agree with your comments. The only problem with the jv route is that it wouldn't solve our funding issue. Even if we were able to fund Alpala, there won't be any significant free cash flow for ten years and in the meantime the company would bleed to death. The capital markets simply wouldn't be remotely interested in the story.
If we wish to become a major there's only one way - sell Alpala.
By the way, unless it gets taken private (unlikely), I can't see any route back for Mather in an executive capacity.